Kessler Alaina J, Marcellino Bridget K, Niglio Scot A, Petersen Bruce E, Malone Adriana K
Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Case Rep Hematol. 2019 Feb 13;2019:2907317. doi: 10.1155/2019/2907317. eCollection 2019.
Plasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. While there is no standard of care for PBL, current recommendations include dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), with or without bortezomib. We report an aggressive case of HIV-negative plasmablastic lymphoma and discuss the challenge in establishing a diagnosis. We review the literature regarding this disease and current recommendations for treatment.
浆母细胞淋巴瘤（PBL）和浆母细胞性浆细胞骨髓瘤（PCM）有许多重叠的特征。临床关联有助于区分这两种疾病。人类免疫缺陷病毒（HIV）阴性的PBL是一种罕见疾病，这使得诊断更具挑战性。虽然PBL没有标准的治疗方案，但目前的建议包括剂量调整的EPOCH（依托泊苷、长春新碱、多柔比星、环磷酰胺和泼尼松），可联合或不联合硼替佐米。我们报告一例侵袭性HIV阴性浆母细胞淋巴瘤病例，并讨论诊断过程中遇到的挑战。我们回顾了关于这种疾病的文献以及当前的治疗建议。
